Health care stocks fall as lawmakers, patients push for changes to their business models

Health care stocks fall as lawmakers, patients push for changes to their business models


UnitedHealth Group signage is displayed on a monitor on the floor of the New York Stock Exchange.

Michael Nagle | Bloomberg | Getty Images

Shares of major health-care companies fell as much as 5% on Wednesday as investors feared pressure from lawmakers and patients could force changes to their business models.

The declining stocks include UnitedHealth Group, Cigna and CVS Health, which operate three of the nation’s largest private health insurers and drug supply chain middlemen called pharmacy benefit managers, or PBMs. They also own pharmacy businesses. Shares of all three companies were down at least 4.8% in early afternoon trading.

The stock reaction on Wednesday appeared to be in response to new bipartisan legislation that aims to break up PBMs, which was first reported by the Wall Street Journal. PBMs have faced years-long scrutiny from Congress and the Federal Trade Commission over allegations they inflate drug costs for patients to boost their profits. 

The share moves also come as insurance companies and their practices face heightened public criticism following the fatal shooting of Brian Thompson, the CEO of UnitedHealth Group’s insurance arm, last week. Health stocks had already fallen in the days after Thompson’s killing.

A Senate bill, sponsored by Sens. Elizabeth Warren,  D-Mass., and Josh Hawley, R-Mo., would force the companies that own health insurers or PBMs to divest their pharmacy businesses within three years, the Journal reported. The lawmakers told the Journal that a companion bill is scheduled to be introduced in the House on Wednesday.

“PBMs have manipulated the market to enrich themselves—hiking up drug costs, cheating employers, and driving small pharmacies out of business,” Warren said in a release. “My new bipartisan bill will untangle these conflicts of interest by reining in these middlemen.”

The release added that healthcare companies that own both PBMs and pharmacies are a “gross conflict of interest that enables these companies to enrich themselves at the expense of patients and independent pharmacies.”

The largest PBMs – UnitedHealth Group’s Optum Rx, CVS Health’s Caremark and Cigna’s Express Scripts – are all owned by or connected to health insurers. They collectively administer about 80% of the nation’s prescriptions, according to the FTC.

PBMs sit at the center of the drug supply chain in the U.S., negotiating rebates with drug manufacturers on behalf of insurers, large employers and federal health plans. They also create lists of medications, or formularies, that are covered by insurance and reimburse pharmacies for prescriptions.

The FTC has been investigating PBMs since 2022. 

— CNBC’s Bertha Coombs contributed to this report



Source

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
Health

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit

The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]

Read More
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More